These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 8096625)
1. Long-term correction of rat model of Parkinson's disease by gene therapy. Jiao S; Gurevich V; Wolff JA Nature; 1993 Apr; 362(6419):450-3. PubMed ID: 8096625 [TBL] [Abstract][Full Text] [Related]
2. [Intracerebral grafting of ex vivo transgene muscle cells in rat model of parkinsonism]. Xu Q; Tian J; Zhang J Zhonghua Wai Ke Za Zhi; 1997 Jan; 35(1):5-9. PubMed ID: 10374497 [TBL] [Abstract][Full Text] [Related]
3. [Intracerebral transplantation of genetically modified cells for Parkinson's disease]. Tang Z; Ying Q; Peng L Zhonghua Wai Ke Za Zhi; 1997 Jan; 35(1):10-2. PubMed ID: 10374498 [TBL] [Abstract][Full Text] [Related]
4. Long term gene therapy of Parkinson's disease using immortalized rat glial cell line with tyrosine hydroxylase gene. Zhuo M; Xu DH; Cao L; Xu LF; Yu FR; Zheng ZC; Liu XY Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Dec; 35(12):1066-71. PubMed ID: 14673496 [TBL] [Abstract][Full Text] [Related]
5. In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase. Leff SE; Rendahl KG; Spratt SK; Kang UJ; Mandel RJ Exp Neurol; 1998 Jun; 151(2):249-64. PubMed ID: 9628761 [TBL] [Abstract][Full Text] [Related]
6. Transplantation of bone marrow stromal cells containing the neurturin gene in rat model of Parkinson's disease. Ye M; Wang XJ; Zhang YH; Lu GQ; Liang L; Xu JY; Chen SD Brain Res; 2007 Apr; 1142():206-16. PubMed ID: 17336273 [TBL] [Abstract][Full Text] [Related]
7. [Gene therapy of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and GTP cyclohydrolase genes in rat model of Parkinson's disease]. Lu LL; Su Y; Duan CL; Zhao CL; Su YJ; Wu J; Zhao HY; Xu QY; Yang H Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1528-32. PubMed ID: 15500713 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease. Lu L; Zhao C; Liu Y; Sun X; Duan C; Ji M; Zhao H; Xu Q; Yang H Brain Res Brain Res Protoc; 2005 May; 15(1):46-51. PubMed ID: 15878150 [TBL] [Abstract][Full Text] [Related]
9. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease. Bouchez G; Sensebé L; Vourc'h P; Garreau L; Bodard S; Rico A; Guilloteau D; Charbord P; Besnard JC; Chalon S Neurochem Int; 2008 Jun; 52(7):1332-42. PubMed ID: 18372079 [TBL] [Abstract][Full Text] [Related]
10. Combined treatment of neurotrophin-3 gene and neural stem cells is ameliorative to behavior recovery of Parkinson's disease rat model. Gu S; Huang H; Bi J; Yao Y; Wen T Brain Res; 2009 Feb; 1257():1-9. PubMed ID: 19111525 [TBL] [Abstract][Full Text] [Related]
11. Astrocyte-specific expression of tyrosine hydroxylase after intracerebral gene transfer induces behavioral recovery in experimental parkinsonism. Segovia J; Vergara P; Brenner M Gene Ther; 1998 Dec; 5(12):1650-5. PubMed ID: 10023444 [TBL] [Abstract][Full Text] [Related]
12. An experimental study on rat model of parkinsonism by gene therapy. Xu Q; Tian J; Zhang J; Yang H; Zheng S; Liu Y Chin Med J (Engl); 1998 Feb; 111(2):154-9. PubMed ID: 10374378 [TBL] [Abstract][Full Text] [Related]
13. [Expression of foreign tyrosine hydroxylase gene in the rat model of Parkinson's disease]. Jiang ZH; Ni ZM; Zhou CF; Cao L; Zheng ZC; Liu XY; Zhao YC; Chen SD Sheng Li Xue Bao; 1997 Apr; 49(2):141-5. PubMed ID: 9812848 [TBL] [Abstract][Full Text] [Related]
14. Generation of DOPA-producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Lundberg C; Horellou P; Mallet J; Björklund A Exp Neurol; 1996 May; 139(1):39-53. PubMed ID: 8635567 [TBL] [Abstract][Full Text] [Related]
15. [The changes of striatal dopamine levels in the brain in rat models for Parkinson's disease after gene therapy]. Tong H; Zhang J; Xu Q Zhonghua Yi Xue Za Zhi; 1996 Jul; 76(7):490-2. PubMed ID: 9275495 [TBL] [Abstract][Full Text] [Related]
16. Levodopa induction of Fos immunoreactivity in rat brain following partial and complete lesions of the substantia nigra. Cole DG; Growdon JH; DiFiglia M Exp Neurol; 1993 Apr; 120(2):223-32. PubMed ID: 8491280 [TBL] [Abstract][Full Text] [Related]
17. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease. Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539 [TBL] [Abstract][Full Text] [Related]
18. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Henry B; Crossman AR; Brotchie JM Exp Neurol; 1998 Jun; 151(2):334-42. PubMed ID: 9628768 [TBL] [Abstract][Full Text] [Related]
19. Intracerebral grafting of genetically modified cells. Applications to a rat model of Parkinson's disease. Shimohama S; Fisher LJ; Gage FH Adv Neurol; 1993; 60():744-8. PubMed ID: 8093583 [No Abstract] [Full Text] [Related]
20. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Bensadoun JC; Déglon N; Tseng JL; Ridet JL; Zurn AD; Aebischer P Exp Neurol; 2000 Jul; 164(1):15-24. PubMed ID: 10877911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]